Alvotech Eyeing US Aflibercept Biosimilar Approval This Year With FDA Acceptance
Teva Holds US Commercialization Rights; Market Opened By Amgen Last Year
Alvotech has followed its European filing for a biosimilar to Regeneron’s Eylea (aflibercept) 2mg with acceptance for review from the US Food and Drug Administration for its AVT06 candidate.
